This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout
by Zacks Equity Research
By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for Canadians.
Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab
by Zacks Equity Research
Bruker (BRKR) completes the installation of its 1.2 (GHz) Avance nuclear magnetic resonance (NMR) spectrometer at the Leibniz Forschungsinstitut f??r Molekulare Pharmakologie in Berlin.
Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch
by Zacks Equity Research
Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.
National Vision (EYE) Gains Market Share Despite Macro Woes
by Zacks Equity Research
National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.
Thermo Fisher (TMO) Expands Central Lab Footprint in Kentucky
by Zacks Equity Research
Thermo Fisher (TMO) announces expansion of its central laboratory operations in Kentucky. The new space in Covington will be in addition to its existing central lab in Highland Heights.
Neogen (NEOG) Expands in Food Safety With Petrifilm Feeder Launch
by Zacks Equity Research
Neogen (NEOG) launches Petrifilm Automated Feeder, which allows automatic feeding and enumeration of up to 300 petrifilm plates in 33 minutes. The system improves the efficiency of food safety testing labs.
Quest Diagnostics (DGX) Inks Deal to Acquire Allina Health
by Zacks Equity Research
Quest Diagnostics (DGX) signs an agreement to acquire Allina Health's select laboratory assets. The deal is aimed at expanding Quest Diagnostics' laboratory services across Minnesota and western Wisconsin.
Charles River (CRL) Inks CDMO Deal With Gates Institutes
by Zacks Equity Research
Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.
Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance
by Zacks Equity Research
Asensus Surgical (ASXC) announces an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital to lease its Senhance Surgical System.
Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS
by Zacks Equity Research
Alcon (ALC) gets FDA 510(k) clearance for its Unity VCS and Unity CS. The company will start a thorough program to get real-world feedback before the systems' commercial launch in 2025.
Inspira (IINN) Unveils Business Targets for 2024-25
by Zacks Equity Research
Inspira (IINN) discloses business goals for 2024-25 with the rapid promotion of INSPIRA ART100 and the development of INSPIRA ART (Gen 2).
Thermo Fisher (TMO) Unveils New Research Laboratory in WI
by Zacks Equity Research
Thermo Fisher (TMO) announces a new 72,500-square-foot clinical research laboratory building at its good manufacturing practices lab in Middleton, WI
Haemonetics (HAE) Expands VASCADE Line With New Limited Launch
by Zacks Equity Research
Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.
The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of 300% and 1.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The Joint Corp. (JYNT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
The Joint Corp. (JYNT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The Joint Corp. (JYNT) Moves 10.1% Higher: Will This Strength Last?
by Zacks Equity Research
The Joint Corp. (JYNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Joint (JYNT) Rises 30% as Q4 Earnings Beat on Higher Clinics
by Zacks Equity Research
The Joint (JYNT) expects 2024 system-wide sales to be within $530-$545 million.
The Joint Corp. (JYNT) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 133.33% and 3.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) to Report Q4 Earnings: Here Are the Key Drivers
by Zacks Equity Research
The Joint's (JYNT) fourth-quarter 2023 results are likely to reflect higher expenses and patient volumes.
Select Medical (SEM) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 16.13% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Cigna (CI) Nearing a Medicare Advantage Divestment Deal?
by Zacks Equity Research
Cigna's (CI) Medicare Advantage unit's divestment is expected to fetch around $3-$4 billion.
Cigna (CI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 1.65% and 2.32%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) Forays Into West Virginia Chiropractic Market
by Zacks Equity Research
The Joint's (JYNT) new facility is positioned near the West Virginia University campus, at a high-traffic shopping center.
The Joint (JYNT) Q2 Earnings Miss Estimates, 2023 View Down
by Zacks Equity Research
The Joint (JYNT) expects to open 100-120 franchised clinics in 2023 compared with 121 opened last year.
The Joint Corp. (JYNT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of -133.33% and 1.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?